Acadia Healthcare heads into its Q1 2026 earnings release carrying one of the most contested short positions in the healthcare sector — and a month of dramatic repositioning on both sides.
Short interest remains exceptionally heavy, at 22.6% of the free float. That is the dominant feature of the setup. The bearish position has fallen sharply over the past month — down 20% from late March highs above 26% — but a sharp weekly jump of nearly 11% shows shorts are not retreating cleanly. Days to cover run close to eight days on official FINRA data, meaning any sustained buying pressure would take considerable time to absorb. The ORTEX short score of 63 ranks the stock in just the 9th percentile on short interest across the universe, a reminder that this is a structurally high-short-interest name. Borrow conditions, however, tell a different story: cost to borrow has eased to below 0.5% and availability is ample, meaning there is no friction preventing new short positions from being established ahead of the print.
Options traders have tilted modestly more defensive in recent days. The put/call ratio is running at 0.47, about 1.5 standard deviations above its 20-day average of 0.41 — elevated, but well below the 52-week high of 1.57 seen during prior periods of stress. The stock itself has moved sharply: up 20% over the past month to $27.58, recovering from a deep sell-off. That recovery sets a high bar. The last confirmed earnings event in February triggered a 30% single-day move and a 40% gain over five days — the kind of volatility that explains why the stock is both heavily shorted and attracting active options interest.
The analyst community has become incrementally more constructive. TD Cowen raised its target to $30 yesterday while maintaining a Buy rating, and UBS lifted its target to $31 two weeks ago — both moves coming after the stock's recovery. The mean price target across the Street now sits at $24, which is actually below the current price of $27.58. Skeptics highlight rising clinical expenses, labour cost pressures, and overhang from government investigations. Bulls point to structural demand in behavioural health, a stock trading at roughly 8.8x EV/EBITDA — not demanding for the sector — and the possibility that management's operational review drives margin improvement. Bellwether holders including Wellington Management and BlackRock each hold more than 12% of shares, and Greenlight Capital added nearly 2.5 million shares in Q4, suggesting at least some conviction-level buying at lower prices.
The earnings print is therefore less a referendum on whether Acadia can grow and more a test of whether it can demonstrate margin progress credible enough to justify a stock that has already raced past the consensus price target.
See the live data behind this article on ORTEX.
Open ACHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
